Literature DB >> 21525170

Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.

Judith Naud1, Josée Michaud, Stéphanie Beauchemin, Marie-Josée Hébert, Michel Roger, Stéphane Lefrancois, Francois A Leblond, Vincent Pichette.   

Abstract

Chronic renal failure (CRF) leads to decreased drug renal clearance due to a reduction in the glomerular filtration rate. However, little is known about how renal failure affects renal metabolism and elimination of drugs. Because both depend on the activity of uptake and efflux by renal transporters as well as enzymes in tubular cells, the purpose of this study was to investigate the effects of CRF on the expression and activity of select renal drug transporters and cytochrome P450. Two groups of rats were studied: control and CRF (induced by 5/6 nephrectomy). Compared with control rats, we observed reductions in the expression of both protein and mRNA of Cyp1a, sodium-dependent phosphate transport protein 1, organic anion transporter (Oat)1, 2, and 3, OatK1/K2, organic anion-transporting polypeptide (Oatp)1 and 4c1, P-glycoprotein, and urate transporter 1, whereas an induction in the protein and mRNA expression of Mrp2, 3, and 4 and Oatp2 and 3 was observed. Cyp3a expression remained unchanged. Similar results were obtained by incubating a human proximal tubule cell line (human kidney-2) with sera from CRF rats, suggesting the presence of uremic modulators. Finally, the renal elimination of [(3)H]digoxin and [(14)C]benzylpenicillin was decreased in CRF rats, compared with controls, as shown by a 4- and 9-fold accumulation, respectively, of these drugs in kidneys of rats in CRF. Our results demonstrate that CRF affects the expression and activity of several kidney drug transporters leading to the intrarenal accumulation of drugs and reduced renal clearance that could, at least partially, explain the tubular toxicity of many drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525170     DOI: 10.1124/dmd.111.039115

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  37 in total

Review 1.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

2.  Integrative biology identifies shared transcriptional networks in CKD.

Authors:  Sebastian Martini; Viji Nair; Benjamin J Keller; Felix Eichinger; Jennifer J Hawkins; Ann Randolph; Carsten A Böger; Crystal A Gadegbeku; Caroline S Fox; Clemens D Cohen; Matthias Kretzler
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

3.  Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein.

Authors:  Yasmine F Ibrahim; Rabab A Moussa; Asmaa M A Bayoumi; Al-Shaimaa F Ahmed
Journal:  Inflammopharmacology       Date:  2019-08-22       Impact factor: 4.473

4.  Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection.

Authors:  J D Momper; Y Zhao; R Shapiro; K S Schonder; Y Gao; P S Randhawa; R Venkataramanan
Journal:  Transpl Infect Dis       Date:  2012-10-02       Impact factor: 2.228

5.  Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.

Authors:  Yosuke Suzuki; Hiroki Itoh; Fuminori Sato; Kanako Kawasaki; Yukie Sato; Takashi Fujioka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

6.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

7.  Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.

Authors:  A Adhipatria P Kartamihardja; Takahito Nakajima; Satomi Kameo; Hiroshi Koyama; Yoshito Tsushima
Journal:  Br J Radiol       Date:  2016-07-26       Impact factor: 3.039

Review 8.  The impact of drug transporters on adverse drug reaction.

Authors:  Yan Zhou; Guo-Qiang Zhang; Yu-Hui Wei; Jian-Ping Zhang; Guo-Rong Zhang; Jiang-Xia Ren; Hao-Gang Duan; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-01-22       Impact factor: 2.441

Review 9.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Aleksandra Galetin; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-08-09       Impact factor: 4.009

10.  CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Authors:  Yosuke Suzuki; Takashi Fujioka; Fuminori Sato; Kunihiro Matsumoto; Nanako Muraya; Ryota Tanaka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino; Hiroki Itoh
Journal:  Br J Clin Pharmacol       Date:  2015-10-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.